TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31862740
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (most commonly morphine)
Study: 28917070
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of sweets
Study: 28917070
Drug: Weekly consumption
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly consumption of carbonated beverages
Study: 28917070
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of carbonated beverages
Study: 28917070
Drug: Weekly consumption
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly consumption of energy drinks
Study: 28917070
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of energy drinks
Study: 28917070
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of daily sweets consumption with age
Study: 28917070
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of daily sweets consumption with carbonated beverages
Study: 28917070
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of daily sweets consumption with energy drinks
Study: 28917070
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of daily sweets consumption with high fat food
Study: 28917070
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of daily sweets consumption with BMI
Study: 18167250
Drug: ALA 600
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA 600 mg/d in normal saline 250 ml given by intravenous drip infusion once a day for 14 days
Study: 18167250
Drug: Radix salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix salviae 20 ml by intravenous drip infusion once a day for 14 days
Study: 9703298
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg of estradiol daily
Study: 9703298
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg of estradiol daily
Study: 9703298
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of estradiol daily
Study: 9703298
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered estradiol
Study: 8020522
Drug: iomeprol 150
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 150 mgI/ml
Study: 8020522
Drug: iopamidol 150
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iopamidol 150 mgI/ml
Study: 2644144
Drug: Cyclosporin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (7.5 mg.kg‐1.day‐1)
Study: 947969
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline sulfate orally
Study: 27755433
Drug: Postoperative 40 mg
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative 40 mg bromelain every 6 hours for 6 days (Group B)
Study: 27755433
Drug: Preoperative 4 mg
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection (Group C)
Study: 27755433
Drug: Preoperative 4 mg
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection plus postoperative 40 mg bromelain every 6 hours for 6 days (Group D)
Study: 24633493
Drug: Metformin (Glucophage(®)
Normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Glucophage(®) 500 mg) 1 tablet twice daily
Study: 24633493
Drug: Sitagliptin (Januvia(®)
Normalized name: sitagliptin Oral Tablet [Januvia]
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin (Januvia(®) 100 mg) 1 tablet/day
Study: 21736768
Drug: Enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched virgin olive oil (EVOO) (961·17 mg/kg oil)
Study: 21736768
Drug: Control virgin
Normalized name: ALLERGENIC EXTRACT, QUECUS RUBRA, ALBA, AGRIFOLA, VIRGIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control virgin olive oil (VOO) (288·89 mg/kg oil)
Study: 17443133
Drug: Ruboxistaurin 96
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin 96 mg/day orally
Study: 14594866
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of carbohydrates (CHO)
Study: 26625709
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D-fortified snack bar (2000 mg/d Ca and 25 µg/d vitamin D) consumed 2 snack bars/d for 9 weeks
Study: 22431837
Drug: 800 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU/d of vitamin E (α‐tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α‐lipoic acid (E/C/ALA)
Study: 22431837
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of coenzyme Q 3 times/d
Study: 19192127
Drug: All medication
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medication arms
Study: 18278696
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (ebm) implementation in oncology
Study: 2175584
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg perindopril
Study: 17676252
Drug: Illicit drug
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit drug use
Study: 10980912
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment of dyslipidemia using lovastatin
Study: 8256106
Drug: Lariam (mefloquine)
Normalized name: mefloquine hydrochloride Oral Tablet [Lariam]
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lariam (mefloquine) 250 mg on alternate weeks
Study: 8256106
Drug: Fansidar (sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (sulfadoxine and pyrimethamine) one tablet weekly
Study: 31898526
Drug: Hand-washing with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-washing with soap at key times and weekly nail clipping
Study: 26701977
Drug: 1.25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/L Ca (1.25 Ca), n=212
Study: 26701977
Drug: 1.75 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mmol/L Ca (1.75 Ca), n=213
Study: 25683256
Drug: Salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3 g/day for 7 days)
Study: 12692782
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation (CAD) therapy
Study: 24386861
Drug: Standard intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intermittent androgen deprivation (IAD) therapy
Study: 24386861
Drug: Modified intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intermittent androgen deprivation (IAD) therapy
Study: 18821290
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (intramuscular injections of testosterone enanthate every three weeks for 12 months)
Study: 12558678
Drug: Preoperative neoadjuvant
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative neoadjuvant therapy for early stage locally advanced breast cancer
Study: 3245859
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17‐propionate cream
Study: 8722606
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17‐propionate ointment
Study: 140084
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone acetonide cream
Study: 7065664
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone acetonide ointment
Study: 8722606
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17‐propionate cream and ointment
Study: 1548248
Drug: Clonidine (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (approximately 0.005 mg/kg/day)
Study: 31572243
Drug: Autonomy-enhancing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomy-enhancing treatment (AET), 15-session group-based
Study: 29873089
Drug: Opioid misuse
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid misuse (defined as use of illicit or prescription opioids without a prescription or not as directed in the previous 6 months)
Study: 26714287
Drug: CYP3A5 genotype-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A5 genotype-based tacrolimus dosing
Study: 20393454
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily regimen of tacrolimus
Study: 18592826
Drug: Extra-fine hydrofluoroalkane-beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine hydrofluoroalkane-beclomethasone (200 microg daily via an Autohaler)
Study: 18592826
Drug: Fluticasone dry
Normalized name: fluticasone Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone dry powder inhaler (200 microg daily via a Diskus)
Study: 16117451
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of 300 IU/kg heparin for total body weight (TBW)
Study: 16117451
Drug: Dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 300 IU/kg heparin for calculated lean body mass (LBM)
Study: 12297361
Drug: Amoxycillin-clavulanate 2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanate 2000/125 mg, twice daily
Study: 12297361
Drug: Amoxycillin-clavulanate 1000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanate 1000/125 mg, three times daily
Study: 10726961
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg bolus infusion)
Study: 9166360
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration to stimulate the pregnant uterus or ripen the cervix
Study: 8445237
Drug: Malotilate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malotilate (500 mg three times a day)
Study: 3088739
Drug: hydroflumethiazide 50
Normalized name: hydroflumethiazide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroflumethiazide 50 mg, Rauwolfia serpentina 50 mg and potassium chloride 625 mg (HFRK)
Study: 3088739
Drug: clopamide 5
Normalized name: clopamide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopamide 5 mg, reserpine 0.1 mg and dihydroergocristine 0.5 mg (CRE)
Study: 20194698
Drug: SP+AS+PQ (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP+AS+PQ (0.75 mg/kg of body weight)
Study: 16204902
Drug: Immediate anti-H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate anti-H. pylori treatment and oral ferrous sulfate
Study: 16204902
Drug: Delayed anti-H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed anti-H. pylori treatment and oral ferrous sulfate
Study: 16204902
Drug: Only oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only oral ferrous sulfate (H. pylori negative patients)
Study: 16204902
Drug: Delayed anti-H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed anti-H. pylori treatment after one month
Study: 12432836
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection (1:10,000)
Study: 12432836
Drug: Epinephrine plus
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine plus sclerosing agent
Study: 8564089
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 5 mg/kg/d for 36 weeks
Study: 26340744
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (150 mg dabrafenib twice daily combined with 2 mg trametinib once daily)
Study: 26340744
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (after adjustment for treatment switching)
Study: 26340744
Drug: Dabrafenib alone
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib alone (before adjustment for treatment switching)
Study: 27082108
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily
Study: 21404197
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hydration and analgesic on demand)
Study: 18245999
Drug: 0.5% Marcain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Marcain (96 mL, 2 mL/h for 48 hours)
Study: 9605669
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (GLN) 0.5 g/kg/day during MTX neoadjuvant therapy
Study: 9605669
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 40 mg/m2 to 100 mg/m2 weekly for 3 weeks
Study: 8273984
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of omeprazole daily
Study: 8273984
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of omeprazole daily
Study: 2658396
Drug: telenzepine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: telenzepine 3 mg once-daily at bedtime
Study: 2658396
Drug: pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 50 mg two times daily
Study: 31678098
Drug: LOR-mod (moderate-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOR-mod (moderate-dose Lorexys)
Study: 31678098
Drug: BUP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP (standard dose bupropion)
Study: 31678098
Drug: LOR-low (subtherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOR-low (subtherapeutic dose Lorexys)
Study: 20965577
Drug: RTL1000 (≤60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTL1000 (≤60 mg)
Study: 13680036
Drug: L‐NMMA 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 0.3 mg/kg iv
Study: 13680036
Drug: L‐NMMA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 1 mg/kg iv
Study: 13680036
Drug: L‐NMMA 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 3 mg/kg iv
Study: 13680036
Drug: L‐NMMA 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 6 mg/kg iv
Study: 10900778
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Support (school-based anti-bullying intervention with additional support)
Study: 10900778
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without Support (school-based anti-bullying programme without additional support)
Study: 8737127
Drug: Comparator antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin, or amoxycillin)
Study: 1570234
Drug: Low-dose Troleandomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Troleandomycin (TAO) therapy
Study: 24949654
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin glulisine initiated at a fifth (20%) the dose of insulin glargine
Study: 24949654
Drug: Maximized dose
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximized dose of sitagliptin to 100 mg
Study: 23185923
Drug: Intrathecal neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal neostigmine 25 microg combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Study: 23185923
Drug: Saline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.5 ml) combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Study: 15923431
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen (Irinotecan 180 mg/m² on day 1 with LV5FU2 regimen)
Study: 10832123
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (rt-PA 50 mg, 10 mg as a bolus plus 40 mg in 60 min)
Study: 10832123
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (conventional therapy)
Study: 1639462
Drug: captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (25 mg b.i.d.) for 4 days
Study: 6436868
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1 g
Study: 6436868
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 2 g
Study: 6436868
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 4 g
Study: 6436868
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (Control)
Study: 11736725
Drug: Ulcer healing
Normalized name: Ulcer healing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulcer healing treatment followed by maintenance therapy
Study: 7909049
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release theophylline, 200 mg 12 hourly
Study: 28042649
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (selenomethionine 83 mcg/day for four months)
Study: 16849403
Drug: NBI-42902 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-42902 (5 mg)
Study: 16849403
Drug: NBI-42902 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-42902 (150 mg)
Study: 12570823
Drug: Leukocytapheresis (LCAP)
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytapheresis (LCAP) weekly for 5 weeks, then once every 4 weeks as maintenance therapy
Study: 12570823
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone (h-PSL) 30-40 mg/day for moderately severe and 60-80 mg/day for severe patients, then gradually tapered
Study: 9090733
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment only
Study: 8477962
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13 to 15 mg daily)
Study: 28621011
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (8 weekly 75-min classes)
Study: 12559536
Drug: Amiodarone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone and verapamil 240 mg/day (group VER)
Study: 12559536
Drug: Amiodarone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone and metoprolol 100 mg/day (group MET)
Study: 9083316
Drug: Intravaginal misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal misoprostol, 50 microg every 4 hours up to three doses (n = 76)
Study: 9083316
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone gel, 0.5 mg every 6 hours up to three doses (n = 79)
Study: 8472213
Drug: He:Ne laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: He:Ne laser treatment
Study: 8472213
Drug: He:Ne +
Approvals — FDA: no, EMA: no, PMDA: no
Description: He:Ne + Nd:YAG laser treatment
Study: 16546596
Drug: Naltrexone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone administration
Study: 27753111
Drug: HyCoSy (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyCoSy (saline solution)
Study: 26324322
Drug: Stabilization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization treatment
Study: 25452017
Drug: Movement system
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement system impairment-based treatment
Study: 21493422
Drug: Pillar implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pillar implants
Study: 9296429
Drug: Topical 60%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 60% lidocaine tape (Group B)
Study: 9296429
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine mixed with propofol (Group C)
Study: 19926008
Drug: Amlodipine, Lisinopril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, Lisinopril, Doxazosin
Study: 14719298
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment using the eight methods of intelligent turtle (Ling Gui Ba Fa)
Study: 10802401
Drug: Alora placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alora placebo patch
Study: 12621596
Drug: Flumazenil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (2 mg)